Scholar Rock Holding Corp
3.99 %
271.85 %
Yet to be announced
Company Overview
Scholar Rock Holding Corporation is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company's lead product candidate is apitegromab, which is in Phase 3 clinical development for the treatment of spinal muscular atrophy (SMA).
Revenue Sources
PassScholar Rock is a pre-revenue biotechnology company currently in research and development phase. The company is focused on developing novel treatments for serious diseases and has not yet commercialized any products. Given the company's pre-revenue status and its focus on legitimate medical research, there is no indication of revenue from haram sources.
Reliance on Interest
| Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|
Based on the financial data provided, the company shows zero interest income and zero interest expense across all four quarters. Additionally, the company is pre-revenue and still in R&D phase, which means the interest ratio tests should be skipped as per the evaluation criteria for pre-revenue companies.
Operational Ethics
PassBased on available information from SEC filings and company materials, there is no evidence of any significant ongoing associations with entities involved in human rights violations. The company's operations are primarily based in the United States, with no indication of R&D centers or significant operations in Israel or direct ties to the Chinese Communist Party.
Comments